NCT05054374: A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: NF1/2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Endocrine (Hormone Therapy, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have evidence of progression on at least 1 prior line of therapy for metastatic disease which should have included a CDK4/6 inhibitor (e.g., palbociclib/Ibrance, abemaciclib/Verzenio, ribociclib/Kisqali) in combination with endocrine therapy
Exclusions: Patients with untreated/unstable symptomatic brain metastases or leptomeningeal disease – see trial for details; Patients with prior therapy with mirdametinib or any other MEK1/2 inhibitor (e.g., selumetinib, trametinib, cobimetinib, binimetinib) at any time before the start of treatment

Comments are closed.

Up ↑